Searching map area
#523 Initial efficacy and safety results from ENGOT-Ov60/GOG-3052/RAMP 201: a phase 2 study of avutometinib (VS-6766) ± defactinib in recurrent low-grade serous ovarian cancer (LGSOC)
Join to rate
Ratings 0
Nobody has rated this yet. Be the first!
Lists 0
Join to rate
Elsewhere
Websitedx.doi.org
Instance of
conference paper
Author
Rachel N. Grisham
Susana Banerjee
Carol Aghajanian
Nicoletta Colombo
Subject
low-grade serous carcinoma
References
Wikidata